Treatment of high-grade glioma in children and adolescents

Neuro-Oncology

Volumn 13, Issue 10, 2011, Pages 1049-1058

  MacDonald, T J ^a   Aguilera, D ^a   Kramm, C M ^b  

^a EMORY UNIVERSITY   (United States)

^b MARTIN LUTHER UNIVERSITÄT HALLE WITTENBERG   (Germany)

Author keywords

Glioblastoma; Integrins; Molecular targeted therapy; Pediatrics; Pontine glioma

Indexed keywords

6 O BENZYLGUANINE; BEVACIZUMAB; CARMUSTINE; CEDIRANIB; CETUXIMAB; CILENGITIDE; CISPLATIN; CYTARABINE; DACARBAZINE; DOXORUBICIN; ENZASTAURIN; ERLOTINIB; ETOPOSIDE; GEFITINIB; HYDROXYUREA; IFOSFAMIDE; IRINOTECAN; LOMUSTINE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; MK 0752; NIMOTUZUMAB; PREDNISONE; PROCARBAZINE; TEMOZOLOMIDE; THALIDOMIDE; TOPOTECAN; UNINDEXED DRUG; VALPROIC ACID; VELIPARIB; VINCRISTINE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTROCYTOMA; BONE MARROW SUPPRESSION; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER RADIOTHERAPY; CANCER SURGERY; DENDRITIC CELL; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; EXTERNAL BEAM RADIOTHERAPY; GENE MUTATION; GLIOMA; HEARING LOSS; HIGH GRADE GLIOMA; HUMAN; MAINTENANCE THERAPY; MAXIMUM TOLERATED DOSE; MOLECULAR BIOLOGY; MOLECULARLY TARGETED THERAPY; MULTIPLE CYCLE TREATMENT; NEUTRON CAPTURE THERAPY; PATHOPHYSIOLOGY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PONTINE GLIOMA; PROGNOSIS; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); TOXICITY;

ADOLESCENT; BRAIN NEOPLASMS; CHILD; CLINICAL TRIALS AS TOPIC; GLIOMA; HUMANS; MEDICAL ONCOLOGY; NEOPLASM GRADING;

EID: 80755125613     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nor092     Document Type: Article

References (87)

1. Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007;114:97-109. (Pubitemid 47103521)
2. Kaatsch P, Rickert CH, Kuhl J, Schuz J, Michaelis J. Population-based epidemiologic data on brain tumors in German children. Cancer. 2001;92:3155-3164. (Pubitemid 33136212)
3. Reddy AT, Wellons JC, III. Pediatric high-grade gliomas. Cancer J. 2003;9:107-112.
4. Sanders RP, Kocak M, Burger PC, Merchant TE, Gajjar A, Broniscer A. High-grade astrocytoma in very young children. Pediatr Blood Cancer. 2007;49:888-893. (Pubitemid 350022440)
5. Qaddoumi I, Sultan I, Gajjar A. Outcome and prognostic featuresinpediatric gliomas: a review of 6212 cases from the Surveillance, Epidemiology, and End Results database. Cancer. 2009;115:5761-5770.
6. Kramm CM, Wagner S, Van GS, et al. Improved survival after gross total resection of malignant gliomas in pediatric patients from the HIT-GBM studies. Anticancer Res. 2006;26:3773-3779. (Pubitemid 44701458)
7. Broniscer A, Gajjar A. Supratentorial high-grade astrocytoma and diffuse brainstem glioma: two challenges for the pediatric oncologist. Oncologist. 2004;9:197-206. (Pubitemid 38452119)
8. Pollack IF, Hamilton RL, James CD, et al. Rarity of PTEN deletions and EGFR amplification in malignant gliomas of childhood: results from the Children's Cancer Group 945 cohort. J Neurosurg. 2006;105:418-424. (Pubitemid 44954773)
9. Paugh BS, Qu C, Jones C, et al. Integrated molecular genetic profiling of pediatric high-grade gliomas reveals key differences with the adult disease. J Clin Oncol. 2010;28:3061-3068.
10. Khatua S, Peterson KM, Brown KM, et al. Overexpression of the EGFR/FKBP12/HIF-2alpha pathway identified in childhood astrocytomas by angiogenesis gene profiling. Cancer Res. 2003;63:1865-1870. (Pubitemid 36460850)
11. Liang ML, Ma J, Ho M, et al. Tyrosine kinase expression in pediatric high grade astrocytoma. J Neurooncol. 2008;87:247-253.
12. Bax DA, Gaspar N, Little SE, et al. EGFRvIII deletion mutations in pediatric high-grade glioma and response to targeted therapy in pediatric glioma cell lines. Clin Cancer Res. 2009;15:5753-5761.
13. Zarghooni M, Bartels U, Lee E, et al. Whole-genome profiling of pediatric diffuse intrinsic pontine gliomas highlights platelet-derived growth factor receptor alpha and poly (ADP-ribose) polymerase as potential therapeutic targets. J Clin Oncol. 2010;28:1337-1344.
14. Gilbertson RJ, Hill DA, Hernan R, et al. ERBB1 is amplified and overexpressed in high-grade diffusely infiltrative pediatric brain stem glioma. Clin Cancer Res. 2003;9:3620-3624. (Pubitemid 37169226)
15. Haas-Kogan D, Shalev N, Wong M, Mills G, Yount G, Stokoe D. Protein kinase B (PKB/Akt) activity is elevated in glioblastoma cells due to mutation of the tumor suppressor PTEN/MMAC. Curr Biol. 1998;8:1195-1198. (Pubitemid 28494720)
16. Pollack IF, Hamilton RL, Burger PC, et al. Akt activation is a common event in pediatric malignant gliomas and a potential adverse prognostic marker: a report from the Children's Oncology Group. J Neurooncol. 2010;99:155-163.
17. Faury D, Nantel A, Dunn SE, et al. Molecular profiling identifies prognostic subgroups of pediatric glioblastoma and shows increased YB-1 expression in tumors. J Clin Oncol. 2007;25:1196-1208. (Pubitemid 46640565)
18. Bax DA, Mackay A, Little SE, et al. A distinct spectrum of copy number aberrations in pediatric high-grade gliomas. Clin Cancer Res. 2010;16:3368-3377.
19. Schiffman JD, Hodgson JG, VandenBerg SR, et al. Oncogenic BRAF mutation with CDKN2A inactivation is characteristic of a subset of pediatric malignant astrocytomas. Cancer Res. 2010;70:512-519.
20. Pollack IF, Hamilton RL, Sobol RW, et al. IDH1 mutations are common in malignant gliomas arising in adolescents: a report from the Children's Oncology Group. Childs Nerv Syst. 2011;27:87-94.
21. Setty P, Hammes J, Rothamel T, et al. A pyrosequencing-based assay for the rapid detection of IDH1 mutations in clinical samples. J Mol Diagn. 2010;12:750-756.
22. Pollack IF, Finkelstein SD, Burnham J, et al. Age and TP53 mutation frequency in childhood malignant gliomas: results in a multi-institutional cohort. Cancer Res. 2001;61:7404-7407. (Pubitemid 32995024)
23. Pollack IF, Finkelstein SD, Woods J, et al. Expression of p53 and prognosis in children with malignant gliomas. N Engl J Med. 2002;346:420-427. (Pubitemid 34437697)
24. Montagut C, Settleman J. Targeting the RAF-MEK-ERK pathway in cancer therapy. Cancer Lett. 2009;283:125-134.
25. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352:997-1003. (Pubitemid 40349502)
26. Pollack IF, Hamilton RL, Sobol RW, et al. O6-methylguanine-DNA methyltransferase expression strongly correlates with outcome in childhood malignant gliomas: results from the CCG-945 Cohort. J Clin Oncol. 2006;24:3431-3437. (Pubitemid 46638900)
27. Donson AM, Addo-Yobo SO, Handler MH, Gore L, Foreman NK. MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma. Pediatr Blood Cancer. 2007;48:403-407. (Pubitemid 46340105)
28. Schlosser S, Wagner S, Muhlisch J, et al. MGMT as a potential stratification marker in relapsed high-grade glioma of children: the HIT-GBM experience. Pediatr Blood Cancer. 2010;54:228-237.
29. Pollack IF, Hamilton RL, Sobol RW, et al. Mismatch repair deficiency is an uncommon mechanism of alkylator resistance in pediatric malignant gliomas: A report from the children's oncology group. Pediatr Blood Cancer. 2010;55:1066-1071.
30. Broniscer A, Laningham FH, Sanders RP, Kun LE, Ellison DW, Gajjar A. Young age may predict a better outcome for children with diffuse pontine glioma. Cancer. 2008;113:566-572.
31. Angelini P, Hawkins C, Laperriere N, Bouffet E, Bartels U. Post mortem examinations in diffuse intrinsic pontine glioma: challenges and chances. J Neurooncol. 2011;101:75-81.
32. Barrow J, Adamowicz-Brice M, Cartmill M, et al. Homozygous loss of ADAM3A revealed by genome-wide analysis of pediatric high-grade glioma and diffuse intrinsic pontine gliomas. Neuro Oncol. 2011;13:212-222.
33. Bodey B, Siegel SE, Kaiser HE. Up-regulation of VEGF expression and related neo-angiogenesis in childhood high-grade gliomas: implications for anti-angiogenic anti-neoplastic therapy. In Vivo. 2006;20:511-518. (Pubitemid 44184108)
34. Wolff JE, Driever PH, Erdlenbruch B, et al. Intensive chemotherapy improves survival in pediatric high-grade glioma after gross total resection: results of the HIT-GBM-C protocol. Cancer. 2010;116:705-712.
35. Wolff JE, Classen CF, Wagner S, et al. Subpopulations of malignant gliomas in pediatric patients: analysis of the HIT-GBM database. J Neurooncol. 2008;87:155-164.
36. Antonelli M, Buttarelli FR, Arcella A, et al. Prognostic significance of histological grading, p53 status, YKL-40 expression, and IDH1 mutations in pediatric high-grade gliomas. J Neurooncol. 2010;99:209-215.
37. Thorarinsdottir HK, Santi M, McCarter R, et al. Protein expression of platelet-derived growth factor receptor correlates with malignant histology and PTEN with survival in childhood gliomas. Clin Cancer Res. 2008;14:3386-3394.
38. MacDonald TJ, Pollack IF, Okada H, Bhattacharya S, Lyons-Weiler J. Progression-associated genes in astrocytoma identified by novel microarray gene expression data reanalysis. Methods Mol Biol. 2007;377:203-222.
39. Aaberg-Jessen C, Christensen K, Offenberg H, et al. Low expression of tissue inhibitor of metalloproteinases-1 (TIMP-1) in glioblastoma predicts longer patient survival. J Neurooncol. 2009;95:117-128.
40. Gu J, Zhang C, Chen R, et al. Clinical implications and prognostic value of EMMPRIN/CD147 and MMP2 expression in pediatric gliomas. Eur J Pediatr. 2009;168:705-710.
41. Ganigi PM, Santosh V, Anandh B, Chandramouli BA, Sastry KV. Expression of p53, EGFR, pRb and bcl-2 proteins in pediatric glioblastoma multiforme: a study of 54 patients. Pediatr Neurosurg. 2005;41:292-299. (Pubitemid 41636332)
42. Zhang JG, Kruse CA, Driggers L, et al. Tumor antigen precursor protein profiles of adult and pediatric brain tumors identify potential targets for immunotherapy. J Neurooncol. 2008;88:65-76.
43. Hargrave D, Bartels U, Bouffet E. Diffuse brainstem glioma in children: critical review of clinical trials. Lancet Oncol. 2006;7:241-248. (Pubitemid 43286454)
44. Sposto R, Ertel IJ, Jenkin RD, et al. The effectiveness of chemotherapy for treatment of high grade astrocytoma in children: results of a randomized trial. A report from the Children's Cancer Study Group. J Neurooncol. 1989;7:165-177. (Pubitemid 19182070)
45. Geyer JR, Finlay JL, Boyett JM, et al. Survival of infants with malignant astrocytomas. A report from the Children's Cancer Group. Cancer. 1995;75:1045-1050.
46. Finlay JL, Boyett JM, Yates AJ, et al. Randomized phase III trial in childhood high-grade astrocytoma comparing vincristine, lomustine, and prednisone with the eight-drugs-in-1-day regimen. Children's Cancer Group. J Clin Oncol. 1995;13:112-123.
47. Fouladi M, Hunt DL, Pollack IF, et al. Outcome of children with centrally reviewed low-grade gliomas treated with chemotherapy with or without radiotherapy on Children's Cancer Group high-grade glioma study CCG-945. Cancer. 2003;98:1243-1252. (Pubitemid 37099910)
48. Finlay JL, Dhall G, Boyett JM, et al. Myeloablative chemotherapy with autologous bone marrow rescue in children and adolescents with recurrent malignant astrocytoma: outcome compared with conventional chemotherapy: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2008;51:806-811.
49. Dunkel IJ, Garvin JH, Jr, Goldman S, et al. High dose chemotherapy with autologous bone marrow rescue for children with diffuse pontine brain stem tumors. Children's Cancer Group. J Neurooncol. 1998;37:67-73. (Pubitemid 28073577)
50. MacDonald TJ, Arenson EB, Ater J, et al. Phase II study of high-dose chemotherapy before radiation in children with newly diagnosed highgrade astrocytoma: final analysis of Children's Cancer Group Study 9933. Cancer. 2005;104:2862-2871. (Pubitemid 41798299)
51. Chintagumpala MM, Friedman HS, Stewart CF, et al. A phase II window trial of procarbazine and topotecan in children with high-grade glioma: a report from the children's oncology group. J Neurooncol. 2006;77:193-198. (Pubitemid 44419755)
52. Wagner S, Peters O, Fels C, et al. Pegylated-liposomal doxorubicin and oral topotecan in eight children with relapsed high-grade malignant brain tumors. J Neurooncol. 2008;86:175-181. (Pubitemid 350263415)
53. Baruchel S, Diezi M, Hargrave D, et al. Safety and pharmacokinetics of temozolomide using a dose-escalation, metronomic schedule in recurrent paediatric brain tumours. Eur J Cancer. 2006;42:2335-2342. (Pubitemid 44316901)
54. Broniscer A, Chintagumpala M, Fouladi M, et al. Temozolomide after radiotherapy for newly diagnosed high-grade glioma and unfavorable low-grade glioma in children. J Neurooncol. 2006;76:313-319.
55. Nicholson HS, Kretschmar CS, Krailo M, et al. Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group. Cancer. 2007;110:1542-1550. (Pubitemid 47463069)
56. Broniscer A, Gururangan S, MacDonald TJ, et al. Phase I trial of singledose temozolomide and continuous administration of o6-benzylguanine in children with brain tumors: a pediatric brain tumor consortium report. Clin Cancer Res. 2007;13:6712-6718. (Pubitemid 350206808)
57. Cohen KJ, Pollack IF, Zhou T, et al. Temozolomide in the treatment of high-grade gliomas in children: a report from the Children's Oncology Group. Neuro Oncol. 2011;13:317-323.
58. Cohen KJ, Heideman RL, Zhou T, et al. Temozolomide in the treatment of children with newly diagnosed diffuse intrinsic pontine gliomas: a report from the Children's Oncology Group. Neuro Oncol. 2011;13:410-416.
59. Jakacki RI, Yates A, Blaney SM, et al. A phase I trial of temozolomide and lomustine in newly diagnosed high-grade gliomas of childhood. Neuro Oncol. 2008;10:569-576.
60. Narayana A, Kunnakkat S, Chacko-Mathew J, et al. Bevacizumab in recurrent high-grade pediatric gliomas. Neuro Oncol. 2010;12:985-990.
61. Gururangan S, Chi SN, Young PT, et al. Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma: a Pediatric Brain Tumor Consortium study. J Clin Oncol. 2010;28:3069-3075.
62. Turner CD, Chi S, Marcus KJ, et al. Phase II study of thalidomide and radiation in children with newly diagnosed brain stem gliomas and glioblastoma multiforme. J Neurooncol. 2007;82:95-101.
63. Pollack IF, Jakacki RI, Blaney SM, et al. Phase I trial of imatinib in children with newly diagnosed brainstem and recurrent malignant gliomas: a Pediatric Brain Tumor Consortium report. Neuro Oncol. 2007;9:145-160. (Pubitemid 46580316)
64. Fouladi M, Nicholson HS, Zhou T, et al. A phase II study of the farnesyl transferase inhibitor, tipifarnib, in children with recurrent or progressive high-grade glioma, medulloblastoma/primitive neuroectodermal tumor, or brainstem glioma: a Children's Oncology Group study. Cancer. 2007;110:2535-2541. (Pubitemid 350174941)
65. Broniscer A, Baker SJ, Stewart CF, et al. Phase I and pharmacokinetic studies of erlotinib administered concurrently with radiotherapy for children, adolescents, and young adults with high-grade glioma. Clin Cancer Res. 2009;15:701-707.
66. Geyer JR, Stewart CF, Kocak M, et al. Aphase I and biology study of gefitinib and radiation in children with newly diagnosed brain stem gliomas or supratentorial malignant gliomas. Eur J Cancer. 2010;46:3287-3293.
67. Warren K, Jakacki R, Widemann B, et al. Phase II trial of intravenous lobradimil and carboplatin inchildhood brain tumors: a report from the Children's Oncology Group. Cancer Chemother Pharmacol. 2006;58:343-347. (Pubitemid 43800737)
68. Desgrosellier JS, Cheresh DA. Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer. 2010;10:9-22.
69. Stupp R, Hegi ME, Neyns B, et al. Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. J Clin Oncol. 2010;28:2712-2718.
70. MacDonald TJ, Stewart CF, Kocak M, et al. Phase I clinical trial of cilengitide in children with refractory brain tumors: Pediatric Brain Tumor Consortium Study PBTC-012. J Clin Oncol. 2008;26:919-924. (Pubitemid 351398085)
71. Memorial Sloan-Kettering Cancer Center. External beam radiation therapy and cetuximab followed by irinotecan and cetuximab for children and young adults with newly diagnosed diffuse pontine tumors and high-grade astrocytomas (POE08-01). Available at: http://clinicaltrials.gov/ct2/show/NCT01012609. Accessed September 30, 2010.
72. Bode U, Buchen M, Warmuth-Metz M, et al. Final report of a phase II trial of nimotuzumab in the treatment of refractory and relapsed highgrade gliomas in children and adolescents. J Clin Oncol. 2006;24(Suppl. 18):1522.
73. Bode U, Windelberg M, Massimino M, et al. Phase III trialof nimotuzumab for the treatment of newly diagnosed diffuse intrinsic pontine gliomas in children and adolescents. J Clin Oncol. 2008;26(Suppl. 15):2058.
74. Pediatric Brain Tumor Consortium. Enzastaurin in treating young patients with refractory primary CNS tumors. Available at: http://clinicaltrials. gov/ct2/show/NCT00503724. Accessed September 30, 2010.
75. Pediatric Brain Tumor Consortium, National Cancer Institute. AZD2171 in treating young patients with recurrent, progressive, or refractory primary CNS tumors. Available at: http://clinicaltrials.gov/ct2/show/NCT00326664?term=PBTC- 020&rank=1. tAccessed January 25, 2011.
76. Liau LM, Prins RM, Kiertscher SM, et al. Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment. Clin Cancer Res. 2005;11:5515-5525. (Pubitemid 41060828)
77. Wheeler CJ, Black KL, Liu G, et al. Vaccination elicits correlated immune and clinical responses in glioblastoma multiforme patients. Cancer Res. 2008;68:5955-5964.
78. Ardon H, De Vleeschouwer S, Van Calenbergh F, et al. Adjuvant dendritic cell-based tumour vaccination for children with malignant brain tumours. Pediatr Blood Cancer. 2010;54:519-525.
79. Masoudi A, Elopre M, Amini E, et al. Influence of valproic acid on outcome of high-grade gliomas in children. Anticancer Res. 2008;28:2437-2442.
80. Children's Oncology Group, National Cancer Institute. Vorinostat and radiation therapy followed by maintenance therapy with vorinostat in treating younger patients with newly diagnosed pontine glioma. Available at: http://www.clinicaltrials.gov/ct2/show/NCT01189266? term=vorinostat&rank=83. Accessed September 30, 2010.
81. Osaka Medical College. Boron neutron capture therapy, radiation therapy, and temozolomide in treating patients with newly diagnosed glioblastoma multiforme. Available at: http://clinicaltrials.gov/ct2/show/NCT00974987. Accessed September 30, 2010.
82. Penn State University. A study using allogenic-cytomegalovirus (CMV) specific cells for glioblastoma multiforme (GBM). Available at: http://clinicaltrials.gov/ct2/show/NCT00990496. Accessed September 30, 2010.
83. National Institute of Neurological Disorders and Stroke (NINDS). An open label dose escalation safety study of convection-enhanced delivery of IL13-PE38QQR in patients with progressive pediatric diffuse infiltrating brainstem glioma and supratentorial high-grade glioma. Available at: http://clinicaltrials.gov/ct2/show/NCT00880061. Accessed September 30, 2010.
84. Novartis Pharmaceuticals. A dose finding and safety study of oral LDE225 in children. Available at: http://clinicaltrials.gov/ct2/show/NCT01125800. Accessed September 30, 2010.
85. Wong VC, Ma J, Hawkins CE. Telomerase inhibition induces acute ATM-dependent growth arrest in human astrocytomas. Cancer Lett. 2009;274:151-159.
86. Purow BW, Haque RM, Noel MW, et al. Expression of Notch-1 and its ligands, Delta-like-1 and Jagged-1, is critical for glioma cell survival and proliferation. Cancer Res. 2005;65:2353-2363. (Pubitemid 40490146)
87. Pediatric Brain Tumor Consortium, National Cancer Institute. ABT-888 and temozolomide in treating young patients with recurrent or refractory CNS tumors. Available at: http://www.clinicaltrials.gov/ct2/show/NCT00946335?term=PBTC- 027&rank=1. Accessed January 25, 2011.